Because pituitary GH release is inhibited by GIH and hypothalamic secretion of this peptide seems to be mainly dependent onp-adrenergic regulation,we have investigated if BAB could modify the pattern of GH response to GRF-29 in 5SN (3V,2F;7.8-9.6 y) and lF; .Blood samples for GH where collected from -15'to+60'according the following testsf A)Propranolol(1 mg/kg,as iv bolus at -6O8);B)GRF(1 mcg/kg,as iv bolus at O');C)Propranolol(as tn A)+GRF!as in B height velocity and partial GH deficiency in response to two pharmacological tests (maximum peak 11 ng/ml) received GRF for 6 months (10 mcg/kg/day) as a subcutaneous injectlon (8 p.m.). 24-hours GH secretion was studied before and after 3 months of treatment : SmC dosage and a IV GRF test (2 mcg/kg) was done before and after 6 months of treatment. Lower leg length was studied every 3 weeks by knemometry and statural growth at 3 months intervals.
Height velocity increased in 5 cases from 2.5 + 0.5 to 4.4 5 1.1 cm for the 6 months period and showed no change in 2 cases. Knemometric growth rate is subject to wide variations and is d~f -ficult to take into account. There was no sign of desensitizat~on: 24-hour secretion (mx peak and I.C.) was higher after 3 months treatment (m = 16.2 2 7.5 ng/ml and 3.7 + 1.2 ng/ml/rnin befor?, 29 2 17.9 ng/ml and 4.5 + 2.9 ng/ml/min afterw~rds), as was the GH peak in the IV GRF test after 6 months treatment ( m = 36.1 ng/ml before, 47.8 ng/ml afterwards). SmC level was h~gher on average after 6 months treatment (1.9 + 1 U/m1 and 0.8 + 0.5 U/ml befor? treatment). The analysis of the various parameters (GH secretion, SmC) provided no elements to account for the lack of therapeutlc response in the 2 cases. These results suggest that GRF treatment may be considered as a therapeutlc alternative in GH deficienc~es.
and SANOFI-RECHERCHE -MONTPELLIER (FRANCE) EFFECTS OF GROWTH-HORMONE -RELEASING HORMONE (GRF) IN 5 CHILDREN WITH IMPAIRED GROWTH HORMONE (GH) SECRETION.
5 children (8.24+/-3.63 years) with growth retardation (3.4 +/-0.9 DS)bone age retardation (3.13+/-2.40 years) and insufficient growth velocity (3.9+/-0.6 cmlyear) related with complete (n=2) or partial (n=3) GH deficiency were treated with a daily dose of 300 mcg GRF administred subcutaneously (SC)every other week for a 6 months period. GH response to SC GRF administration, GH and GRF antibodies and somatomedins were studied on repeated blood samples performed on day 1 and day 8 of the first week of treatment as well as at the end of the 6 months therapy. Growth velocity increased to 6.16+/-1.17 cmlyear. 3 of the 5 patients have accelerated growth mainly for the first 3 months. Linear growth was increased in complete (c2.5 and 4.3 em/year) more than in partial (+0.4, +0.8 and +3.3 cmlyear) GH deficient children. The area under the GH curve after GRF administration was 1050.7+/-767.7 on day 1, 472. I+/-103.2 on day 8 and 631.9 +/-148.1 ng/ml x min. after 6 months therapy. No major change in other hormonal evaluations was noted. These results confirm that GRF can stimulate linear growth in some GH deficient children and lead to discuss the role of limiting factors in its long term effects such as desensitization, antibodies or somatostatin.
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The Middlesex Hospital, London, Vl . UNITED KINGDOH PULSATILE GROWTH HORMONE RELEASING HORMONE TREATMENT OF CH DEFICIENCY We have treated 1 1 prepubertal children (7M;4F) with idiopathic GH deficiency due to pituitary hypoplasia using GHRH 1-40. This was administered subcutaneously for 4 pulses at 3 hourly intervals at night in a dose of 1-2pg/kg/pulse. Blood samples for GH concentrations were taken at 20 minute intervals for 24 hours before treatment and throughout the study monthly at night.
Pulsatile GH secretion was induced in 10 children from the first night of treatment and the response augmented with time.
Growth velocity in 8 of 1 1 children increased from 3.3cm/yr (range 1.7 to 4.9) before treatment to 6.9cmIyr (range 5-8.5) on CHRH. 2 children had no change in height velocity and one had a progressive diminution of CH secretion and a fall in growth velocity.
CHRH (lug/kg) was also administered intravenously to all children before treatment and at 3 monthly intervals. Although a GH response was seen on all occasions, the responses predicted neither the GH concentrations nor the growth velocities obtained on long term s.c. treatment.
Pulsatile administration of GHRH 1-40 was effective in inducing GH secretion and promoting growth acceleration in the majority of children with idiopathic GH deficiency. 
INSULIN-LIKE GROWTH FACTOR I / SOMATOMEDIN C (IGF I/
..
Tne bicchenical and growth r e s p x~~ t o CHW(1-29)NH2 therapy were studied in 1 8 preplbertal CE-deficient children (14 idiopathic, 3 cranial irradiation, 1 mpto-optic dysplasia; 16 male, 2 fmiale, mean ags 9.5 years, tmge 6.e -14.2 years). 81 deficiency was defined as a peak GI-I to stinlulation of less than 7 nU/1. Farteen childrw bad reoeived t X 3 t r e a m t which was stopped at least 3 mnths before the trial. CEIRIi was given as Mce daily sc ir+ct,iorrs in individual cbses of 250 pg (children less than M kg bw), and 500 pg ( @ & r than 20 kg). Peak m n m 81 r e s p w to CHFN before treatrent was 5.8 + 6.3 mU/1 ( m a n + SE) and after 3 mnth? 27.4 + 4.2 nD/l; indicating m desensitisatior~ effect. rnirteen of t k 1 8 shwed an i n c m t in height velocity after 3 rlxlnth? tkrapy, i n 6 this was greater than 2 cm/year and i n 3 greater than 5 an/year.
I h e children shwed a greater h e w t velocity on 0!Ri than on M. Eight children have mpleted 6 mntis therapy and 3 b e sh3wn an i n c m n t in heqht velocity of 0.4, 2.5, and 3.1 adyear. Wre was m correlation between the gmnh respme at 3 mth? and pre-treamt Q4 respnse t o CMW. In conclusion, we have sh3wn tt~t twice daily sc 0!Ri therapy is a safe treabmt which p m t e d linear grmrth at 3 m t h ? in 13 of 1 8 M-deficient children. Hcwever, predictors of gxd g w t h r z s p r~?~ cwld m t be identified.
Starting from Cohn fraction IV of human plasma we earlier described a multiple step procedure which resulted in ug amount of IGF I/SmC of relative high purity (200 vU/pg)+.
In the meanwhile we have further modified this method: 20 grs. of acetone dried Cohn fraction IV are suspended in 1% NaCl/fornic acid, pH 3.0. After precipitation of the IGF I containing proteins in the supernatant by addition of 5 M NaCl the precipitate is resuspended in 2 N acetic acid (AA) /ethanol (1:4). Denatured proteins are discarded by centrifugation, and after evaporation the supernatant is chromatographed on Sephadex G 50 in 1 N AA.
IGF I containing fractions (approx. 12 pg IGF I, purity of approx. 90%) are purified by 1mmobilineR isoelectric focusing (IEF) (pH 8-10). The IGF I band, focusing at pH 8.3 finally is purified using a HPLC reversed phase C-18 column in a 25-65% acetonitrile gradient cont. 0.05% TFA. IGF I elutes in a single peak at approx. Res. 18, 107 (1984) 
